Every material Form 8-K Neurogene Inc. has filed with the SEC since June 29, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Neurogene Inc. reported third quarter 2026 results, with a net loss of $29.0 million for the three months ended September 30, 2026, up from $21.0 million a year earlier. Higher R&D and G&A spending, driven largely by NGN-401 development and stock-based compensation, drove the increase, and the company said its cash position is expected to fund operations into the first quarter of 2029.
Net loss was $29.0 million for Q3 2026, compared with $21.0 million for Q3 2025.
R&D expenses rose to $23.5 million from $17.2 million, mainly for NGN-401 clinical trial and manufacturing activities.
G&A expenses rose to $8.9 million from $6.6 million, mainly from higher non-cash stock-based compensation.
Cash, cash equivalents and short-term investments were $359.7 million as of September 30, 2026, expected to fund operations into the first quarter of 2029.
Neurogene reported second quarter 2026 results, with a net loss of $34.5 million versus $22.0 million a year earlier, driven by higher R&D and G&A expenses including a one-time stock-based compensation catch-up charge. The company also said an oversubscribed public offering of about $144 million gross proceeds extends its cash runway into the first quarter of 2029, and it reported updated Phase 1/2 data for NGN-401 in Rett syndrome.
Net loss was $34.5 million for the quarter ended June 30, 2026, compared with $22.0 million a year earlier.
R&D expenses rose to $25.5 million from $19.4 million; G&A expenses rose to $11.2 million from $6.7 million.
Pro forma cash, cash equivalents and short-term investments were about $360.2 million, including about $134.8 million of net proceeds from the July 2, 2026 offering.
Topline Embolden registrational data are expected in the second half of 2027.
Neurogene agreed on June 30, 2026 to sell 3,500,000 common shares at $30.00 each, with pre-funded warrants for up to 666,666 more shares offered in place of common stock for some investors. Underwriters exercised in full their option to buy 624,999 additional shares on July 1, 2026, and the company expects net proceeds of about $134.8 million. The company says these proceeds, plus existing cash, will fund operations into the first quarter of 2029, but the sale adds new shares outstanding for existing shareholders.
3,500,000 common shares offered at $30.00 per share, plus pre-funded warrants for up to 666,666 shares
Underwriters exercised in full their option for up to 624,999 additional shares on July 1, 2026
Expected net proceeds of approximately $134.8 million after underwriting discounts and estimated expenses
Offering expected to close July 2, 2026; company expects cash to last into the first quarter of 2029
Neurogene released updated Phase 1/2 results for its NGN-401 gene therapy in females with Rett syndrome, reporting 47 developmental milestones gained across 10 participants with follow-up of 12 to 30 months. The company reported no plateau or loss of milestones and no new treatment-related serious adverse events since its October 2025 data cutoff. The filing contains clinical data only, with no financial results or guidance changes, and topline results from the Embolden registrational trial are expected in the second half of 2027.
47 total developmental milestones gained across 10 participants, an average of 4.7 per participant, as of the June 16, 2026 data cutoff
Follow-up ranged from 12 to 30 months, with no plateau observed and no milestones lost
No new treatment-related serious adverse events reported since the October 2025 data cutoff; no treatment-related SAEs or DLTs in Embolden as of June 16, 2026
Embolden registrational trial dosing is complete with 25 participants; topline results expected in 2H 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Neurogene Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →